Mineral and bone metabolism in dialysis: Towards unified patient care?

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 7-9

  Pelletier, Solenne ^a   Fouque, Denis ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; SEVELAMER;

ARTICLE; BONE METABOLISM; CANADA; CHRONIC KIDNEY DISEASE; DIALYSIS; HUMAN; HYPERPARATHYROIDISM; MINERAL METABOLISM; MORBIDITY; MORTALITY; PATIENT CARE; PRIORITY JOURNAL;

BONE AND BONES; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; MINERALS; PATIENT CARE; RENAL DIALYSIS;

EID: 78650656639     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq713     Document Type: Article

References (11)

1. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
2. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
3. Pelletier S, Roth H, Bouchet JL et al. Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3062-3070
4. Pelletier S, Roth H, Bouchet JL et al. Mineral and bone status in French maintenance hemodialysis patients: a comparison of June 2005 and June 2008. Néphrol Thér 2005; 6: 11-20
5. Mendelssohn D et al. Interprovincial differences in the achievement of K/DOQI targets of mineral metabolism in Canada. Nephrol Dial Transplant 2011; 26: 156-163
6. Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589
7. Vervloet M, Bencova V, Malberti F et al. "Real-world" use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO Observational Study. Clin Nephrol 2010; 74: 198-208
8. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76: S1-S130
9. Manns BJ, Hodsman A, Zimmerman DL et al. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2009; 55: 800-812
10. Uhlig K, Berns JS, Kestenbaum B et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2009; 55: 773-799
11. Goldsmith DJ, Covic A, Fouque D et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 25: 3823-3831